In a significant step forward for lung cancer treatment, the US Food and Drug Administration (FDA) has expanded its approval of Bristol Myers Squibb’s Opdivo (nivolumab). The latest approval allows the immunotherapy to be used in adult patients with resectable non-small cell lung cancer (NSCLC) in combination with platinum-doublet chemotherapy as part of a perioperative […]
Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company, has announced encouraging results from Cohort B of the TACTI-003 (KEYNOTE-PNC-34) Phase IIb trial. The study evaluates the effectiveness of eftilagimod alfa (efti) combined with Merck & Co., Inc.’s KEYTRUDA (pembrolizumab) in treating patients with recurrent or metastatic head and neck squamous cell carcinoma (1L […]
Agenus Inc. (Nasdaq: AGEN), a pioneer in the development of immunological agents for cancer treatment, has recently unveiled promising results from an investigator-sponsored trial (IST) of its novel therapies, botensilimab and balstilimab (BOT/BAL), for treating colon cancer. These findings were presented at the 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress in Munich, […]
In a significant advancement for cancer treatment, AstraZeneca’s Imfinzi (durvalumab) has emerged as the first and only immunotherapy to show a survival benefit in a global Phase III trial for patients with limited-stage small cell lung cancer (LS-SCLC). The ADRIATIC Phase III trial unveiled positive high-level results, revealing that Imfinzi significantly improved both overall survival […]
In a significant stride toward enhancing bladder cancer treatment, Bristol Myers Squibb (NYSE: BMY) announced the U.S. Food and Drug Administration (FDA) approval of Opdivo (nivolumab), in conjunction with cisplatin and gemcitabine, for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), the most prevalent form of bladder cancer. This approval […]
Syncona Ltd, a prominent investor in the life sciences sector, has announced a significant strategic collaboration through its portfolio company, Autolus Therapeutics plc, with BioNTech SE, a trailblazer in next-generation immunotherapies. This partnership marks a pivotal step towards the commercialization of autologous CAR-T programs, pending regulatory approvals. BioNTech’s investment of $200 million in Autolus’ American […]
Bristol Myers Squibb (NYSE: BMY) has announced results from its Phase 3 CheckMate -67T trial, which could revolutionize treatment for patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC). The trial evaluated the subcutaneous formulation of PD-1 immune checkpoint inhibitor Opdivo (nivolumab), co-formulated with Halozyme’s proprietary recombinant human hyaluronidase (rHuPH20), referred to as […]
Roche’s subsidiary, Genentech, has announced a significant breakthrough with the US Food and Drug Administration (FDA) approval of Tecentriq (atezolizumab). This new approval marks a pivotal development in the fight against extensive stage small cell lung cancer (ES-SCLC), as the monoclonal antibody will now be used in combination with chemotherapy as a first-line treatment for […]
Bristol-Myers Squibb’s cancer drug Opdivo (nivolumab) has failed to meet the primary endpoint in the Phase 3 CheckMate -331 trial, designed to assess its effectiveness in small cell lung cancer (SCLC) patients whose condition had relapsed after platinum-based chemotherapy. The trial results reveal that Opdivo did not significantly enhance overall survival compared to the current […]
AstraZeneca has reached a crucial milestone as the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Imfinzi (durvalumab) for the treatment of locally-advanced, unresectable non-small cell lung cancer (NSCLC). This recommendation paves the way for a new treatment option for […]